Gemcitabine
- Generic Name
- Gemcitabine
- Brand Names
- Gemzar
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11F2N3O4
- CAS Number
- 95058-81-4
- Unique Ingredient Identifier
- B76N6SBZ8R
- Background
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...
- Indication
Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.
In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...
- Associated Conditions
- Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
- Associated Therapies
- -
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT06592326
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients
- Conditions
- Interventions
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 29
- Registration Number
- NCT06576635
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06576115
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT06571461
A Study of Gemcitabine/Cisplatin Plus Cemiplimab (REGN2810, Anti-PD-1) With or Without Fianlimab (REGN3767, Anti-LAG-3) in Patients With Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 36
- Registration Number
- NCT06571708
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06548412
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Chemoimmunotherapy Combined with Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 15
- Registration Number
- NCT06546969
- Locations
- 🇺🇸
Maryland Proton Treatment Center, Baltimore, Maryland, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06545955
- Locations
- 🇺🇸
Ferring Investigational Site, Los Angeles, California, United States
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT06538207
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
🇯🇵Kanagawa Cancer Center, Yokohama-shi, Kanagawa, Japan
🇯🇵Seirei Hamamatsu General Hospital, Hamamatsu-shi, Shizuoka, Japan
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- The National Center of Oncology, Azerbaijan
- Target Recruit Count
- 200
- Registration Number
- NCT06531447
- Locations
- 🇦🇿
Elchin Mansurov, Baku, Azerbaijan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.